69 related articles for article (PubMed ID: 1871273)
1. Experimental hepatocellular carcinoma: MR receptor imaging.
Reimer P; Weissleder R; Brady TJ; Yeager AE; Baldwin BH; Tennant BC; Wittenberg J
Radiology; 1991 Sep; 180(3):641-5. PubMed ID: 1871273
[TBL] [Abstract][Full Text] [Related]
2. Receptor imaging: application to MR imaging of liver cancer.
Reimer P; Weissleder R; Lee AS; Wittenberg J; Brady TJ
Radiology; 1990 Dec; 177(3):729-34. PubMed ID: 2243978
[TBL] [Abstract][Full Text] [Related]
3. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging.
Reimer P; Weissleder R; Lee AS; Buettner S; Wittenberg J; Brady TJ
Radiology; 1991 Mar; 178(3):769-74. PubMed ID: 1994416
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
5. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats.
Leveille-Webster CR; Rogers J; Arias IM
Hepatology; 1996 Jun; 23(6):1631-41. PubMed ID: 8675187
[TBL] [Abstract][Full Text] [Related]
6. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.
Weissleder R; Elizondo G; Wittenberg J; Lee AS; Josephson L; Brady TJ
Radiology; 1990 May; 175(2):494-8. PubMed ID: 2326475
[TBL] [Abstract][Full Text] [Related]
7. Use of magnetite particles as a contrast agent for MR imaging of the liver.
Kawamura Y; Endo K; Watanabe Y; Saga T; Nakai T; Hikita H; Kagawa K; Konishi J
Radiology; 1990 Feb; 174(2):357-60. PubMed ID: 2296645
[TBL] [Abstract][Full Text] [Related]
8. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors.
Weissleder R; Reimer P; Lee AS; Wittenberg J; Brady TJ
AJR Am J Roentgenol; 1990 Dec; 155(6):1161-7. PubMed ID: 2122660
[TBL] [Abstract][Full Text] [Related]
9. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging.
Clement O; Frija G; Chambon C; Schouman-Clayes E; Mosnier JF; Poupon MF; Balkau B
Radiology; 1991 Jul; 180(1):31-6. PubMed ID: 2052718
[TBL] [Abstract][Full Text] [Related]
10. Superparamagnetic iron oxide enhanced magnetic resonance imaging of rat liver with hepatocellular carcinoma and benign hyperplastic nodule.
Ishida T; Murakami T; Kato N; Takahashi M; Miyazawa T; Tsuda K; Tomoda K; Narumi Y; Nakamura H
Invest Radiol; 1997 May; 32(5):282-7. PubMed ID: 9140748
[TBL] [Abstract][Full Text] [Related]
11. A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent.
Josephson L; Groman EV; Menz E; Lewis JM; Bengele H
Magn Reson Imaging; 1990; 8(5):637-46. PubMed ID: 1707120
[TBL] [Abstract][Full Text] [Related]
12. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents.
Reimer P; Kwong KK; Weisskoff R; Cohen MS; Brady TJ; Weissleder R
J Magn Reson Imaging; 1992; 2(2):177-81. PubMed ID: 1562768
[TBL] [Abstract][Full Text] [Related]
13. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents.
Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM
Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging.
Senéterre E; Weissleder R; Jaramillo D; Reimer P; Lee AS; Brady TJ; Wittenberg J
Radiology; 1991 May; 179(2):529-33. PubMed ID: 2014305
[TBL] [Abstract][Full Text] [Related]
15. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
[TBL] [Abstract][Full Text] [Related]
16. Arabinogalactan-coated superparamagnetic iron oxide: effect of particle size in liver MRI.
Wisner ER; Amparo EG; Vera DR; Brock JM; Barlow TW; Griffey SM; Drake C; Katzberg RW
J Comput Assist Tomogr; 1995; 19(2):211-5. PubMed ID: 7890843
[TBL] [Abstract][Full Text] [Related]
17. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers.
Ma HL; Xu YF; Qi XR; Maitani Y; Nagai T
Int J Pharm; 2008 Apr; 354(1-2):217-26. PubMed ID: 18191350
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents.
Clément O; Mühler A; Vexler VS; Rosenau W; Berthezène Y; Kuwatsuru R; Brasch RC
Radiology; 1992 Oct; 185(1):163-8. PubMed ID: 1523301
[TBL] [Abstract][Full Text] [Related]
19. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide.
Elizondo G; Weissleder R; Stark DD; Guerra J; Garza J; Fretz CJ; Todd LE; Ferrucci JT
Radiology; 1990 Mar; 174(3 Pt 1):797-801. PubMed ID: 2305063
[TBL] [Abstract][Full Text] [Related]
20. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits.
Taupitz M; Wagner S; Hamm B; Binder A; Pfefferer D
AJR Am J Roentgenol; 1993 Jul; 161(1):193-200. PubMed ID: 8517301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]